Free and complexed prostate-specific antigen serum ratios to predict probability of primary prostate cancer and benign prostatic hyperplasia.

[1]  M Bobbio,et al.  The Effect of Disease-prevalence Adjustments on the Accuracy of a Logistic Prediction Model , 1996, Medical decision making : an international journal of the Society for Medical Decision Making.

[2]  D. Bostwick,et al.  The definition and preoperative prediction of clinically insignificant prostate cancer. , 1996, JAMA.

[3]  U. Stenman,et al.  Purification and characterization of different molecular forms of prostate-specific antigen in human seminal fluid. , 1995, Clinical chemistry.

[4]  W. Catalona,et al.  Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. , 1995, JAMA.

[5]  H. Lilja,et al.  Free and complexed prostate-specific antigen (PSA): in vitro stability, epitope map, and development of immunofluorometric assays for specific and sensitive detection of free PSA and PSA-alpha 1-antichymotrypsin complex. , 1995, Clinical chemistry.

[6]  T. Stamey,et al.  Purification and characterization of prostate-specific antigen (PSA) complexed to alpha 1-antichymotrypsin: potential reference material for international standardization of PSA immunoassays. , 1995, Clinical chemistry.

[7]  J. Oesterling,et al.  Free, complexed and total serum prostate specific antigen: the establishment of appropriate reference ranges for their concentrations and ratios. , 1995, The Journal of urology.

[8]  J. Oesterling,et al.  Should Medicare provide reimbursement for prostate-specific antigen testing for early detection of prostate cancer? Part I: Framing the debate. , 1995, Urology.

[9]  J. Oesterling,et al.  Molecular forms of prostate-specific antigen and the human kallikrein gene family: a new era. , 1995, Urology.

[10]  Alice S. Whittemore,et al.  Logistic regression of family data from case-control studies , 1995 .

[11]  T. Stamey.  Second Stanford Conference on International Standardization of Prostate-Specific Antigen Immunoassays: September 1 and 2, 1994. , 1995, Urology.

[12]  J. Beck,et al.  A critique of the decision analysis for clinically localized prostate cancer. , 1994, The Journal of urology.

[13]  J. Oesterling,et al.  The clinical usefulness of prostate specific antigen: update 1994. , 1994, The Journal of urology.

[14]  O. Nilsson,et al.  Serum prostate specific antigen complexed to alpha 1-antichymotrypsin as an indicator of prostate cancer. , 1993, The Journal of urology.

[15]  D. Hosmer,et al.  Applied Logistic Regression , 1991 .

[16]  O. Nilsson,et al.  Prostate-specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin. , 1991, Clinical chemistry.

[17]  G. Murphy,et al.  A prostate antigen in sera of prostatic cancer patients. , 1980, Cancer research.

[18]  R. Vollmer,et al.  Multivariate statistical analysis for pathologist. Part I, The logistic model. , 1996, American journal of clinical pathology.

[19]  P. Wingo,et al.  Cancer statistics, 1996 , 1996, CA: a cancer journal for clinicians.

[20]  U. Stenman,et al.  A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. , 1991, Cancer research.